Treatment
Medical Care
* If patients are suicidal, homicidal, or gravely disabled, admit them to an inpatient psychiatric unit. Inpatient treatment is mandatory for patients who are dangerous to themselves or others and for patients who cannot take care of themselves.
* Patients who have schizoaffective disorder can greatly benefit from psychotherapy and well as psychoeducational programs.
o They should receive therapy that involves their families, develops their social skills, and focuses on cognitive rehabilitation.
o Psychotherapies should include supportive therapy and assertive community therapy in addition to individual and group forms of therapy and rehabilitation programs.
* Family involvement is needed in the treatment of this particular disorder.
* Treatment includes education about the disorder and its treatment, family assistance in compliance with medications and appointments, and maintenance of structured daily activities (ie, schedule of daily events) for the patient.
Consultations
* Consult a neurologist to rule out neurological disease.
Diet
* No specific diet is recommended for patients with schizoaffective disorder.
Activity
* Restrict activity if patients represent a danger to themselves or to others or if they are gravely disabled. Otherwise, encourage patients who are schizoaffective to continue their normal routines and strengthen their social skills whenever possible.
Medication
Several medications are used to treat schizoaffective disorder. Agent selection depends on whether the depressive or manic subtype is present. Early treatment with medication along with good premorbid function often improves outcomes. In the depressive subtype, combinations of antidepressants (eg, sertraline, fluoxetine) plus an antipsychotic (eg, haloperidol, risperidone, olanzapine) are used. In refractory cases, clozapine has been used as an antipsychotic agent. In the manic subtype, combinations of mood stabilizers (eg, lithium, carbamazepine, divalproex) plus an antipsychotic are used. Of the many medications and combinations available to treat schizoaffective disorder, a few are reviewed below.
Antipsychotics
These agents ameliorate psychosis and aggressive behavior.
Haloperidol (Haldol)
For management of psychosis. Also for motor and vocal tics in children and adults. Mechanism of action not clearly established, but has selective effect on CNS by competitively blocking postsynaptic dopamine (D2) receptors in mesolimbic dopaminergic system; increases in dopamine turnover responsible for tranquilizing effect. With subchronic therapy, depolarization blockade and D2 postsynaptic blockade responsible for antipsychotic action.
Risperidone (Risperdal)
Selective monoaminergic antagonist binds to dopamine D2 receptor with 20 times lower affinity than to 5-HT2 receptors. Also binds to alpha1-adrenergic receptors with lower affinity to H1-histaminergic and alpha2-adrenergic receptors. Improves negative symptoms of psychosis and decreases occurrence of extrapyramidal effects.
Also available in long-acting IM formulation (Risperdal Consta).
Olanzapine (Zyprexa)
Atypical antipsychotic with broad pharmacologic profile across receptor systems (eg, serotonin, dopamine, cholinergic muscarinic, alpha adrenergic, histamine). Antipsychotic effect from antagonism of dopamine and serotonin type 2 receptors. Indicated for treatment of psychosis and bipolar disorder.
Clozapine (Clozaril)
Weak D2-receptor and D1-receptor blocking activity, but noradrenolytic, anticholinergic, antihistaminic, and arousal reaction inhibiting effects are significant. Antiserotonergic properties. Risk of agranulocytosis limits use to patients nonresponsive to or intolerant of classic neuroleptic agents.
Quetiapine (Seroquel)
Newer antipsychotic for long-term management. May antagonize dopamine and serotonin effects. Improvements over earlier antipsychotics include fewer anticholinergic effects and less dystonia, parkinsonism, and tardive dyskinesia.
Ziprasidone (Geodon)
Antagonizes dopamine D2, D3, 5-HT2A, 5-HT2C, 5-HT1A, 5-HT1D, alpha1-adrenergic. Has moderate antagonistic effect for histamine H1. Moderately inhibits reuptake of serotonin and norepinephrine.
Aripiprazole (Abilify)
Improves positive and negative schizophrenic symptoms. Mechanism of action unknown, but hypothesized to differ from that of other antipsychotics. Aripiprazole thought to be partial dopamine (D2) and serotonin (5HT1A) agonist, and antagonizes serotonin (5HT2A). No QTc-interval prolongation noted in clinical trials.
Antidepressants
These agents decrease aggression and treat the underlying illness.
Selective serotonin reuptake inhibitors (SSRIs) are greatly preferred over the other classes of antidepressants. Because the adverse-effect profile of SSRIs is less prominent than the profiles of other drugs, improved compliance is promoted. SSRIs do not have the cardiac arrhythmia risk associated with tricyclic antidepressants. Arrhythmia risk is especially pertinent in overdose, and suicide risk must always be considered when one treats a child or adolescent with a mood disorder.
Physicians are advised to be aware of the following information and to use appropriate caution when they consider treatment with SSRIs in the pediatric population.
In December 2003, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) issued an advisory that most SSRIs are not suitable for use by persons younger than 18 years for treatment of depressive illness. After review, this agency decided that the risks to pediatric patients outweigh the benefits of treatment with SSRIs, except fluoxetine (Prozac), which appears to have a positive risk-benefit ratio in the treatment of depressive illness in patients younger than 18 years.
In October 2003, the US Food and Drug Administration (FDA) issued a public health advisory regarding reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder. This advisory reported suicidality (both ideation and attempts) in clinical trials of various antidepressant drugs in pediatric patients. The FDA has asked that additional studies be performed because suicidality occurred in both treated and untreated patients with major depression and thus could not be definitively linked to drug treatment.
For more information go to the following website: http://emedicine.medscape.com/article/294763-treatment